# Amycretin vs CagriSema: One Dual Agonist vs Two-Drug Amylin Stack
> Note: PeptIQ is not a medical provider. These programs differ in maturity. Educational comparison only.
Novo is playing both sides of the amylin chessboard:
- CagriSema — two drugs (cagrilintide + semaglutide)
- Amycretin — one drug hitting GLP-1 and amylin receptors
That is the clean SEO comparison: fixed combo vs unimolecular dual agonist.
Architecture Difference
| CagriSema | Amycretin | |
|---|---|---|
| Design | Two molecules | One dual agonist molecule |
| Amylin piece | Cagrilintide | Built into amycretin |
| GLP-1 piece | Semaglutide | Built into amycretin |
| Public maturity | Large Phase 3 obesity dataset (REDEFINE) | Early-phase published; Phase 3 advancing |
| Formats | Weekly injectable combo story | Oral daily and SC weekly in development |
Data Maturity Gap (Be Honest)
CagriSema already has Phase 3 mean weight-loss figures in the ~20% neighborhood for the combo, with clear monotherapy comparators.
Amycretin early SC cohorts showed very large mean losses (public summaries around ~10–22% depending on dose/duration part) in smaller, earlier studies — exciting, not yet Phase 3 confirmed at scale.
Oral amycretin added a short-window ~10–13% signal that made the pill narrative real.
Rule: do not crown amycretin the winner because an early 22% mean looks higher than a Phase 3 20% mean from a different design.
Dosing Mental Models
| Program | Public anchors |
|---|---|
| CagriSema maintenance story | Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly |
| Amycretin SC early map | Exploratory weekly exposures including 1.25 / 5 / 20 mg |
| Amycretin oral early map | Daily doses around 50 mg (and higher short-term) |
Phase 3 amycretin ladders will replace early maps.
Who Might Prefer Which Architecture (Conceptual)
Fixed two-drug combo (CagriSema-like)
